280 related articles for article (PubMed ID: 36034423)
1. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
2. Extent of Surgery and the Prognosis of Unilateral Papillary Thyroid Microcarcinoma.
Zhao H; Cui L
Front Endocrinol (Lausanne); 2021; 12():655608. PubMed ID: 34220708
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
Xu S; Huang H; Huang Y; Qian J; Wang X; Xu Z; Liu S; Liu J
JAMA Surg; 2023 Jan; 158(1):73-79. PubMed ID: 36449303
[TBL] [Abstract][Full Text] [Related]
4. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
5. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
7. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
8. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
9. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
10. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
12. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
Dai P; Zhao W; Zheng X; Luo H; Wang X
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
[TBL] [Abstract][Full Text] [Related]
14. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
15. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
[TBL] [Abstract][Full Text] [Related]
16. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
17. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study.
Kuba S; Yamanouchi K; Hayashida N; Maeda S; Adachi T; Sakimura C; Kawakami F; Yano H; Matsumoto M; Otsubo R; Sato S; Fujioka H; Kuroki T; Nagayasu T; Eguchi S
Int J Surg; 2017 Feb; 38():143-148. PubMed ID: 27677707
[TBL] [Abstract][Full Text] [Related]
18. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
19. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]